Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation
- 1 June 2002
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 282 (6) , L1366-L1375
- https://doi.org/10.1152/ajplung.00273.2001
Abstract
Chronic hypoxia (CH) augments endothelium-derived nitric oxide (NO)-dependent pulmonary vasodilation; however, responses to exogenous NO are reduced following CH in female rats. We hypothesized that CH-induced attenuation of NO-dependent pulmonary vasodilation is mediated by downregulation of vascular smooth muscle (VSM) soluble guanylyl cyclase (sGC) expression and/or activity, increased cGMP degradation by phosphodiesterase type 5 (PDE5), or decreased VSM sensitivity to cGMP. Experiments demonstrated attenuated vasodilatory responsiveness to the NO donors S-nitroso- N-acetylpenicillamine and spermine NONOate and to arterial boluses of dissolved NO solutions in isolated, saline-perfused lungs from CH vs. normoxic female rats. In additional experiments, the sGC inhibitor, 1H-[1,2,4]oxadiazolo[4,3- a]quinoxalin-1-one, blocked vasodilation to NO donors in lungs from each group. However, CH was not associated with decreased pulmonary sGC expression or activity as assessed by Western blotting and cGMP radioimmunoassay, respectively. Consistent with our hypothesis, the selective PDE5 inhibitors dipyridamole and T-1032 augmented NO-dependent reactivity in lungs from CH rats, while having little effect in lungs from normoxic rats. However, the attenuated vasodilatory response to NO in CH lungs persisted after PDE5 inhibition. Furthermore, CH similarly inhibited vasodilatory responses to 8-bromoguanosine 3′5′-cyclic monophosphate. We conclude that attenuated NO-dependent pulmonary vasodilation after CH is not likely mediated by decreased sGC expression, but rather by increased cGMP degradation by PDE5 and decreased pulmonary VSM reactivity to cGMP.Keywords
This publication has 29 references indexed in Scilit:
- sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2001
- Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries.American Journal of Physiology-Lung Cellular and Molecular Physiology, 2001
- Segmental vasodilatory effectiveness of inhaled NO in lungs from chronically hypoxic ratsRespiration Physiology, 1998
- Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in ratsBritish Journal of Pharmacology, 1998
- Upregulation of Nitric Oxide Synthase Correlates Temporally With Onset of Pulmonary Vascular Remodeling in the Hypoxic RatHypertension, 1996
- Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.Journal of Clinical Investigation, 1996
- Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung.American Journal of Respiratory Cell and Molecular Biology, 1995
- The Type III Phosphodiesterase Inhibitor Milrinone and Type V PDE Inhibitor Dipyridamole Individually and Synergistically Reduce Elevated Pulmonary Vascular ResistancePulmonary Pharmacology, 1994
- Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive ratsBritish Journal of Pharmacology, 1992
- Interaction of hydrolysis-resistant analogs of cyclic GMP with the phosphodiesterase and light-sensitive channel of retinal rod outer segments.Proceedings of the National Academy of Sciences, 1985